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Persistent Fever and Pancytopenia:
Lupus Flare vs Macrophage Activation Syndrome
Amy McGhee, MD

Introduction
Macrophage activation syndrome (MAS), first named in
1993, is a subcategory of hemophagocytic lymphohistiocytosis (HLH), characterized by prolonged fever, hepatosplenomegaly, pancytopenia, liver dysfunction, and most
notably hyperferritinemia. MAS, in particular, is the term
used to describe secondary HLH, or HLH caused by
rheumatologic conditions. Secondary HLH can also be
associated with other systemic autoimmune diseases,
underlying malignancy, infection, or medications and can
be a life-threatening complication. MAS is characterized
by unwarranted proliferation and stimulation of T cells
and benign macrophages leading to an excessive
inflammatory state with hypersecretion of cytokines.
This, in turn, leads to phagocytosis of normal blood cells
and injury to the organs containing these macrophages
(liver, spleen, bone marrow, lymph nodes). With regard
to rheumatologic conditions, MAS is most often seen
associated with juvenile idiopathic arthritis (incidence of
7-13%) while it is much less commonly seen in systemic
lupus erythematosus (SLE) with an incidence of 0.9-4.6%.
The etiology is unknown, although there are hypotheses.

Case Presentation
A 53 year old female with SLE complicated by lupus
nephritis and lupus anticoagulant initially presented with
a syncopal episode. While walking out of the rheumatologist office, she felt faint and had an assisted fall to
the floor with transient loss of consciousness. The patient
reported approximately 1-2 months of decreased oral
intake, weight loss, daily fevers to 102-103°F, lightheadedness, dry cough, and 1 week of rash on her upper
chest. During this time, her rheumatologist adjusted her
SLE medications, attributing her symptoms to a SLE flare.
Work up during this admission (labs listed in Table 1) ruled
out sepsis as a source of fever. It was determined that her
symptoms and lab abnormalities were likely secondary to a
lupus flare given her fever, rash, constitutional symptoms,
and pancytopenia in the setting of SLE that was difficult
to control. Early macrophage activation syndrome (MAS)
was also on the differential given the elevated ferritin
level. Her symptoms improved with pulse dose steroids
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and resuming mycophenolate mofetil for immunosuppression. The plan was to change this to cyclosporine as
an outpatient to prevent MAS.
Before switching to cyclosporine however, the patient
was readmitted for recurrent fevers, fatigue, diarrhea, and
worsening lab abnormalities. On admission, her physical
exam was significant for fever to 102.4°F, tachycardia,
and dry mucus membranes. Labs are shown in Table
2. The most remarkable finding was a ferritin of 11,741
which was a significant increase from 4,542 during her
last admission. The patient underwent a bone marrow
biopsy, which demonstrated increased macrophages with
hemophagocytic activity, confirming a diagnosis of MAS.

Differential Diagnosis
In an SLE patient with recent flare 4 months ago, a
recurrent lupus flare was highest on the differential as the
patient reported joint pain, skin rash, fevers, weight loss,
and fatigue. Infection is also high on the differential for
a patient on chronic immunosuppression who presents
with fever. An infectious workup was undertaken
including a Right upper quadrant ultrasound, chest CT,
blood cultures, urine cultures, respiratory viral panel,
and transthoracic echo, all of which were negative for
infection. Anti-dsDNA antibodies were unexpectedly
normal and complement levels were unremarkable
which made a SLE flare less likely.
During the initial admission, the hyperferritinemia, an
acute phase reactant, was thought to be elevated in
the setting of a lupus flare or infection. However, the
dramatic increase to 11,741 upon readmission raised
suspicion for MAS. Multiple case reports have described
this diagnostic difficulty in distinguishing between MAS
and a SLE flare. It has been reported that elevation of
ferritin (greater than or equal to 500ug/L) and LDH can
help differentiate as this represents activation of the
mononuclear phagocyte system. Hyperferritinemia has
a sensitivity and specificity of almost 100% for distinguishing between a SLE flare and MAS. Lastly, a bone
marrow biopsy is usually diagnostic for MAS if there is
still uncertainty.
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Table 1. Labs for first admission.
Lab

Result

Lab

Result

WBC (B/L)

1.2

L

AST (U/L)

71

Hemoglobin (g/dL)

7.4

L

ALT (U/L)

23

Platelets (B/L)

178

Alk phosphatase (U/L)

35

Sodium (mmol/L)

137

Lactate (mmol/L)

1.1

Potassium (mmol/L)

4.4

Iron (mcg/dL)

44

Chloride (mmol/L)

103

Iron Binding Capacity (mcg/
dL)

179

Bicarbonate (mmol/L)

22

Iron Saturation (%)

25

BUN (mg/dL)

21

Ferritin (ng/mL)

4542

H

Creatinine (mg/dL)

0.9

ESR (mm/hr)

114

H

Glucose (mg/dL)

127

CRP (mg/dL)

1.50

H

PTT (sec)

42

C3 complement (mg/dL)

79

L

PT (sec)

10.1

C4 complement (mg/dL)

12

INR

0.93

Anti-dsDNA Ab (IU)

25

Total Protein (g/dL)

5.1

L

Haptoglobin (mg/dL)

295

H

Albumin (g/dL)

2.8

L

LDH (IU/L)

396

H

Total bilirubin (mg/dL)

0.2

Vitamin B12 (pg/mL)

433

Direct bilirubin (mg/dL)

<0.2

Folate (ng/mL)

>20

Urinalysis

2+ protein

L

H

H

L

Trace blood
1 RBC 4 WBC

Table 2. Labs upon second admission.
Lab

Result

Lab

Result

WBC (B/L)

0.9

L

AST (U/L)

128

H

Hemoglobin (g/dL)

8.5

L

ALT (U/L)

49

H

Platelets (B/L)

72

L

Alk phosphatase (U/L)

41

Total Protein (g/dL)

5.6

L

Ferritin (ng/mL)

11741 H

Albumin (g/dL)

3.1

L

LDH (IU/L)

1135

Total bilirubin (mg/dL)

0.6
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Outcome and Follow-up
Once the diagnosis of MAS was confirmed, the patient
was treated with cyclosporine, anakinra (IL-1 receptor
blocker), and high dose steroids. These were uptitrated
until the ferritin, leukopenia, and liver function tests
began to improve. Interestingly, in the work-up of the
patient’s pancytopenia, her EBV studies showed a positive
VCA IgG and ENA IgG so the patient was also treated
with IVIG in case an EBV infection was contributing
to the MAS. The patient was discharged home after a
month-long hospitalization. In the next nine months,
her medications were all gradually tapered and she had
a concordant improvement in ferritin, blood counts, and
symptoms.

Discussion
There remain many uncertainties surrounding MAS
including its etiology, treatment, and prognosis. In
one case study of a patient with SLE and MAS, the
patient tested positive for numerous antibodies (ANA,
anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, and peripheral
ANCA antibodies). It was hypothesized that the
overwhelming amount of autoantibodies and immune
complexes bound to normal blood cells trigger
phagocytosis of those cells. It is possible that the quantity
of these autoantibodies and the increased complement
activity during a SLE flare can trigger MAS.
Once the diagnosis of MAS is made, it is important to
initiate therapy quickly as it can be a life-threatening
illness. The cornerstone of therapy is high dose steroids.
Multiple case reports also discuss the importance of
immunosuppressant medications, such as cyclosporine
A and cyclophosphamide in patients who do not respond
to steroids, such as the patient in this report. One study,
in particular, demonstrated 54% of patients with MAS
from systemic autoimmune disease who received only
high dose steroids were resistant to this treatment and
the majority of patients who were treated with both
steroids and immunosuppression had good treatment
response. Another case report demonstrated the fairly
rapid improvement in labs and clinical condition of a
young man who was treated with cyclosporine when
he did not respond to steroids. IVIG is another treatment
option which is especially useful in patients who are
suspected to have an underlying viral infection. Further,

| The Medicine
24Jefferson
5 2015
Published by
DigitalForum
Commons,

the next line of treatment if both steroids and immunosuppression are not effective is biologic agents, such
as anakinra and rituximab. Anakinra is an IL-1 receptor
blocker that has been used effectively in patients
with MAS secondary to SLE which did not respond to
steroids, IVIG, and cyclosporine. There is also evidence
that rituximab is effective in treating resistant MAS. The
patient in this case study did not respond appropriately
to pulse dose steroids, cyclosporine, or IVIG, so she was
started on anakinra and did well after a few weeks on
this regimen.
Further, prognosis is another area of uncertainty in MAS.
There have been no prognostic indicators established
yet but there is evidence suggesting the level of certain
cytokines can be associated with a worse prognosis and
that ferritin levels may help predict outcome. Multiple
studies have found no correlation between ferritin
levels and the severity of disease or outcome; however,
serial ferritin levels may shed more light on prognosis.
The patient in this case report had a ferritin of 4500
on initial admission, which increased to 11,000 on her
subsequent admission indicating lack of response to
therapy. Once anakinra was added and titrated, her
symptoms improved and her ferritin slowly decreased
over the course of weeks. She was safely discharged
home with close follow up.

Key Points
MAS is a potentially life-threatening complication of
rheumatologic diseases, characterized by excessive
activation of benign macrophages which lead to
the phagocytosis of normal blood cells and injury to
surrounding tissues. Common clinical manifestations
include fever, pancytopenia, liver dysfunction, hepatosplenomegaly, and hyperferritinemia. Diagnosis can be
difficult as the signs and symptoms of MAS can mimic
an infection or SLE flare. However, hyperferritinemia and
elevated LDH are characteristic of MAS and may help
distinguish and guide treatment decisions. If uncertainty
remains, a bone marrow biopsy can usually establish
the diagnosis. The best treatment options at this point
include high dose steroids, immunosuppression, IVIG,
and biologics depending on the patient’s laboratory and
clinical response.
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